Jaguar Health, Inc. (JAGX)
NCM · Healthcare · Biotechnology
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
About Jaguar Health, Inc.
Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health. The company focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. Its lead prescription drug is Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase III clinical trial for prophylaxis of diarrhea in adult cancer patients; Phase II clinical trials for rare/orphan disease indications, including short bowel syndrome with intestinal failure and microvillus inclusion disease; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing Mytesi which is in Phase III clinical trial for cancer therapy-related diarrhea, as well as Phase II clinical trial for irritable bowel syndrome; and NP-300, a second-generation antidiarrheal drug that is in Phase I clinical trial for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 3.0M | 3.1M | 3.2M | 20.2M |
| Gross Profit | 2.5M | 2.6M | 1.0M | 19.1M |
| Operating Income | -8.0M | -7.2M | -20.4M | 10.2M |
| Net Income | -10.4M | -9.5M | -23.1M | 8.8M |
| Diluted EPS | $-359.10 | $-219.80 | $nan | $-476.00 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 12.0M | 9.8M | 11.7M | 11.5M |
| Gross Profit | 9.9M | 7.7M | 9.7M | 7.7M |
| Operating Income | -34.4M | -33.9M | -30.8M | -45.1M |
| Net Income | -47.5M | -41.3M | -38.5M | -53.4M |
| Diluted EPS | $-1,129,857.14 | $-29,542.20 | $-4,574.15 | $-803.95 |